Announcement on Implementation Results of Share Repurchase and Share Changes
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Implementation Results of Share Repurchase and Share Changes
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
Beijing Hotgen Biotech Co. Ltd. announced the results of its share repurchase and changes in share structure. The repurchased shares will be held for a year before being sold, with specific conditions regarding their handling outlined. The announcement confirms that the repurchase was executed according to the approved plan without any discrepancies.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Release
Beijing Hotgen Biotech Co. Ltd. on 6ix
Earlier from Beijing Hotgen Biotech
- Announcement on Adjustment of Core Technical Personnel
- Announcement on Voluntary Disclosure of Obtaining "Drug Clinical Trial Approval" for New Indication of Subsidiary's Innovative Drug SGC001 Injection
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Progress in Repurchasing Shares
- Announcement on Voluntary Disclosure of Obtaining the "Drug Clinical Trial Approval Notice" for Subsidiary’s Innovative Drug SGT003 Injection
Later from Beijing Hotgen Biotech
- Announcement on Change of Registered Capital, Amendment to the Articles of Association and Filing of Industrial and Commercial Registration Changes
- Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase I/IIa Clinical Trial of Subsidiary's Innovative Drug SGT003
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- (688068)"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Completion of First Subject Enrollment and Dosing in the Phase II Clinical Study of the Subsidiary's SGC001 Innovative Drug for Indication of "Predicted Severe Acute Pancreatitis"
- (688068)"BEIJING HOTGEN BIOTECH CO., LTD."Report for Q3 2026
Follow Beijing Hotgen Biotech into a list and get an email when it puts out news.
Follow Beijing Hotgen Biotech